• Patients using IDP-126 triple ingredient acne topical had a 50% reduction in acne at 12 weeks than all dual ingredient topicals.
  • Patients with moderate-severe atopic dermatitis present with heterogeneous disease course subtypes which can guide therapy choice and implementation.
  • The majority of psoriasis patients who were treated for 52 weeks with deucravacitinib maintained or lowered cholesterol and triglyceride levels.